Abstract
Background: The 24-week INTREPID (NCT03467425) study in patients with symptomatic COPD demonstrated the clinical benefits of once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25µg vs non-Ellipta multiple-inhaler triple therapy (MITT).
Objective: The cost-effectiveness of FF/UMEC/VI vs MITT was assessed using INTREPID data from a UK perspective.
Methods: Baseline characteristics, efficacy and treatment discontinuation data obtained from INTREPID populated a validated linked risk equation, disease progression model. Treatment effects included forced expiratory volume in 1 second and St George’s Respiratory Questionnaire (derived from CAT score mapping). In the model analysis, patients could discontinue in the first year; an ongoing treatment effect was applied to patients remaining on treatment. UK healthcare resource and drug costs (2020£) were applied; costs and outcomes were discounted at 3.5%. Over a lifetime horizon, model outputs included exacerbation rates, survival, costs, life years (LYs), quality-adjusted LYs (QALYs) and incremental cost-effectiveness ratio per QALY. Sensitivity analyses explored the robustness of results by varying parameter values and assumptions.
Results: LYs and QALYs were greater for FF/UMEC/VI (9.00 LYs; 4.38 QALYs) vs MITT (8.83 LYs; 4.13 QALYs) with a cost saving of £1764 (95% range −£2600, −£678). Across all scenario and sensitivity analyses, FF/UMEC/VI remained the dominant treatment option, with lower costs and improved outcomes.
Conclusions: Compared to MITT, FF/UMEC/VI is predicted to improve health outcomes at lower costs in the UK setting.
Funding: GSK (study 212888; INTREPID study 206854/NCT03467425)
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA78.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021